Dimitrios Iliopoulos, Athos Therapeutics CEO (via website)

Athos, an au­toim­mune and can­cer biotech, is rais­ing $35M for clin­i­cal tri­als

Athos Ther­a­peu­tics is rais­ing a $35 mil­lion Se­ries B, it con­firmed to End­points News. The Tor­rance, CA-based biotech will de­ploy the mon­ey on its AI-based pre­ci­sion small mol­e­cules for au­toim­mune dis­eases and var­i­ous can­cer in­di­ca­tions.

About $10 mil­lion of the ex­pect­ed haul will go to­ward the lead as­set, an in­flam­ma­tion and mu­cos­al heal­ing-tar­get­ed treat­ment for in­flam­ma­to­ry bow­el dis­ease, CEO Dim­itrios Il­iopou­los said in an emailed state­ment. The biotech an­tic­i­pates Phase I topline da­ta by March and plans to start a Phase IIa by the third quar­ter of 2024, he added, not­ing the cap­i­tal will al­so fund it through that study.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.